Choroidal Neovascularization – Pipeline Review, H1 2012

Published : April 2012
No. of Pages : 80

Price:

Choroidal Neovascularization – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Choroidal Neovascularization - Pipeline Review, H1 2012', provides an overview of the Choroidal Neovascularization therapeutic pipeline. This report provides information on the therapeutic development for Choroidal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization. 'Choroidal Neovascularization - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Choroidal Neovascularization.
- A review of the Choroidal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Choroidal Neovascularization pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Choroidal Neovascularization therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Choroidal Neovascularization Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Choroidal Neovascularization 9
Choroidal Neovascularization Therapeutics under Development by Companies 11
Choroidal Neovascularization Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Choroidal Neovascularization Therapeutics – Products under Development by Companies 19
Choroidal Neovascularization Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Choroidal Neovascularization Therapeutics Development 21
QLT Inc. 21
Lpath, Inc. 22
Regeneron Pharmaceuticals, Inc. 23
Promedior, Inc. 24
ESBATech AG 25
Choroidal Neovascularization – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
iSONEP - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Eylea - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ESBA 105 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Lucentis - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Stakel Mediated VTP Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Adalimumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Ranibizumab + Verteporfin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Ranibizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Avastin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Visudyne + Lucentis + Dexamethasone - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Verteporfin Photodynamic Therapy + Ranibizumab + Triamcinolone - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Lucentis + Visudyne - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Lucentis + Visudyne - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Bevacizumab + Visudyne Photodynamic Therapy - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Adalimumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
KH902 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Dexamethasone + Ranibizumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Avastin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Verteporfin Photodynamic Therapy + Triamcinolone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Intravitreal Pentraxin-2 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drug For Ocular Diseases - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rCD59-APT542 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
iSONEP + Lucentis - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
iSONEP + Avastin - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Choroidal Neovascularization Therapeutics – Drug Profile Updates 68
Choroidal Neovascularization Therapeutics – Discontinued Products 75
Choroidal Neovascularization Therapeutics - Dormant Products 76
Choroidal Neovascularization – Product Development Milestones 77
Featured News & Press Releases 77
Jan 03, 2012: Regeneron Announces Settlement Of Patent Litigation With Genentech For US Ophthalmic Sales Of EYLEA Injection 77
Jan 18, 2011: Regeneron And Bayer Start Phase III Trial To Extend Ophthalmology Research & Development Program For VEGF Trap-Eye In Asia 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
Number of Products Under Development for Choroidal Neovascularization, H1 2012 9
Products under Development for Choroidal Neovascularization – Comparative Analysis, H1 2012 10
Number of Products under Development by Companies, H1 2012 12
Number of Products under Investigation by Universities/Institutes, H1 2012 14
Comparative Analysis by Late Stage Development, H1 2012 15
Comparative Analysis by Mid Clinical Stage Development, H1 2012 16
Comparative Analysis by Early Clinical Stage Development, H1 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 18
Products under Development by Companies, H1 2012 19
Products under Investigation by Universities/Institutes, H1 2012 20
QLT Inc., H1 2012 21
Lpath, Inc., H1 2012 22
Regeneron Pharmaceuticals, Inc., H1 2012 23
Promedior, Inc., H1 2012 24
ESBATech AG, H1 2012 25
Assessment by Monotherapy Products, H1 2012 26
Assessment by Combination Products, H1 2012 27
Assessment by Stage and Route of Administration, H1 2012 29
Assessment by Stage and Molecule Type, H1 2012 31
Choroidal Neovascularization Therapeutics – Drug Profile Updates 68
Choroidal Neovascularization Therapeutics – Discontinued Products 75
Choroidal Neovascularization Therapeutics – Dormant Products 76

List of Figures
Number of Products under Development for Choroidal Neovascularization, H1 2012 9
Products under Development for Choroidal Neovascularization – Comparative Analysis, H1 2012 10
Products under Development by Companies, H1 2012 11
Products under Investigation by Universities/Institutes, H1 2012 13
Late Stage Products, H1 2012 15
Mid Clinical Stage Products, H1 2012 16
Early Clinical Stage Products, H1 2012 17
Pre-Clinical Stage Products, H1 2012 18
Assessment by Monotherapy Products, H1 2012 26
Assessment by Combination Products, H1 2012 27
Assessment by Route of Administration, H1 2012 28
Assessment by Stage and Route of Administration, H1 2012 29
Assessment by Molecule Type, H1 2012 30
Assessment by Stage and Molecule Type, H1 2012 31

Choroidal Neovascularization – Pipeline Review, H1 2012

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: